The role of Menin inhibitors in previously untreated, older AML-patients with NPM1 mutations and KMT2A rearrangement is still under investigation in current clinical trials [38] and same applies to triplet combinations like IDH- or FLT3-inhibitors with HMA and venetoclax [39, 40]. The gene discussed is IDH1; the disease is acute myeloid leukemia.